NCL Method ITA-17
In Vitro Induction of Leukocyte Procoagulant Activity by Nanoparticles
Listed in Datasets | publication by group NCL Protocols
Version 2.0b - published on 24 Jul 2020 doi:10.17917/ZQ6R-KD69 - cite this
Licensed under these terms
Description
Leukocyte procoagulant activity (PCA) is accepted as an important component in the onset of disseminated intravascular coagulation (DIC). DIC is common in acute promyelocytic leukemia (APL) and other forms of cancer[1-5]. DIC in cancer patients is often observed after initiation of therapy with cytotoxic oncology drugs that act by altering DNA replication (e.g., doxorubicin, daunorubicin, and vincristin) [3, 6]. Cytotoxic oncology drugs acting by other mechanisms, (e.g., methotrexate and paclitaxel) do not induce DIC [7-8]. DIC is also a common complication in sepsis [9-12]. Cytotoxic drugs (doxorubicin, vincrisitn, and daunorubicin) and endotoxin have previously been shown to induce leukocyte PCA in vitro and DIC in vivo [13-21]. In vitro, doxorubicin-induced leukocyte PCA has previously been linked to DIC in vivo [3].
Content List
- NCL_Method_ITA-17_June2020.pdf(PDF | 354 KB)
Cite this work
Researchers should cite this work as follows:
- Timothy Potter, Barry Neun, Jamie Rodriguez, Anna Ilinskaya, Marina Dobrovolskaia (2020). NCL Method ITA-17. (Version 2.0b). NCI Hub. doi:10.17917/ZQ6R-KD69
Tags
NCL Protocols
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.